Effectiveness of a Pharmacist-based Gout Care Management Programme in a Large Integrated Health Plan: Results from a Pilot Study
Overview
Authors
Affiliations
Objectives: The study objective was to determine the feasibility of using a pharmacist-staffed, protocol-based structured approach to improving the management of chronic, recurrent gout.
Setting: The study was carried out in the outpatient clinic of a single Kaiser Permanente medical centre. This is a community-based clinic.
Participants: We report on 100 consecutive patients between the ages of 21 and 94 (75% men) with chronic or recurrent gout, referred by their primary physicians for the purpose of management of urate-lowering therapy. Patients with stage 5 chronic kidney disease or end-stage kidney disease were excluded.
Interventions: The programme consisted of a trained clinical pharmacist and a rheumatologist. The pharmacist contacted each patient by phone, provided educational and dietary materials, and used a protocol that employs standard gout medications to achieve and maintain a serum uric acid (sUA) level of 6 mg/dL or less. Incident gout flares or adverse reactions to medications were managed in consultation with the rheumatologist.
Primary Outcome Measure: The primary outcome measure was the achievement and maintenance of an sUA of 6 or less for a period of at least 3 months.
Results: In 95 evaluable patients enrolled in our pilot programme, an sUA of 6 mg/dL or less was achieved and maintained in 78 patients with 4 still in the programme to date. Five patients declined to participate after referral, and another 13 patients did not complete the programme. (The majority of these were due to non-adherence.)
Conclusions: A structured pharmacist-staffed programme can effectively and safely lower and maintain uric acid levels in a high percentage of patients with recurrent gout in a primary care setting. This care model is simple to implement, efficient and warrants further validation in a clinical trial.
Zafar S, Hazlewood G, Dhiman K, Charlton A, Then K, Dempsey E ACR Open Rheumatol. 2024; 6(5):276-286.
PMID: 38376004 PMC: 11089442. DOI: 10.1002/acr2.11652.
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares.
Russell M, Ameyaw-Kyeremeh L, DellAccio F, Lapham H, Head N, Stovin C Rheumatology (Oxford). 2023; 63(8):2222-2229.
PMID: 37929968 PMC: 11292051. DOI: 10.1093/rheumatology/kead574.
He Q, Mok T, Sin T, Yin J, Li S, Yin Y JMIR Public Health Surveill. 2023; 9:e45943.
PMID: 37285198 PMC: 10285625. DOI: 10.2196/45943.
Russell M, Rutherford A, Ellis B, Norton S, Douiri A, Gulliford M Lancet Reg Health Eur. 2022; 18:100416.
PMID: 35814340 PMC: 9257653. DOI: 10.1016/j.lanepe.2022.100416.
Improving outcomes for patients hospitalized with gout: a systematic review.
Russell M, Clarke B, Roddy E, Galloway J Rheumatology (Oxford). 2021; 61(1):90-102.
PMID: 34247233 PMC: 8742824. DOI: 10.1093/rheumatology/keab539.